TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02735122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen Tablet
Description: 2 test acetaminophen 500 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen Caplet
Description: 2 commercial acetaminophen 500 mg caplets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen Liquid-filled capsule
Description: 2 commercial ibuprofen 200 mg Liquid-filled capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Tablet
Description: 2 placebo tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Tablet
Description: 2 placebo tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: 2 placebo tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Caplet
Description: 2 placebo caplets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Caplet
Description: 2 placebo caplets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Caplet
Description: 2 placebo caplets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Liquid-filled capsule
Description: 2 placebo Liquid-filled capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Liquid-filled capsule
Description: 2 placebo Liquid-filled capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Liquid-filled capsule
Description: 2 placebo Liquid-filled capsules
Study: NCT01652794

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: Undergo SBRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: Optional correlative studies
Study: NCT03264898

Intervention type: DEVICE
Intervention: Fecal immunochemical test (FIT)
Description: FIT is a type of fecal occult blood test that uses antibodies to hemoglobin to detect blood in stool.
Study: NCT02947230

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored Knowledge Translation
Description: Tailored knowledge translation strategies specific to maintaining and increasing physical mobility with age.
Study: NCT02548897

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: The programming of DBS settings in all participants with bilateral DBS implants in the globus pallidus internus (GPi) and pedunculopontine nucleus (PPN) will be performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroencephalography
Description: An electroencephalography (EEG) will be performed on all participants to better understand the neurophysiological underpinnings of the symptom.
Study: NCT02867930

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: drug for moderate sedation in trans-esophageal echocardiography

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketofol(ketamine+propofol)
Description: drug for moderate sedation in trans-esophageal echocardiography
Study: NCT03514771

Intervention type: DEVICE
Group type: OTHER
Intervention: Fraxel DUAL 1550/1927

Intervention type: DRUG
Group type: OTHER
Intervention: oral isotretinoin
Description: oral isotretinoin

Intervention type: DRUG
Group type: OTHER
Intervention: oral valacyclovir
Description: Oral valacyclovir
Study: NCT02134405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebamipide
Description: Rebamipide 100mg tid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebamipide
Description: Rebamipide 100mg tid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Esomeprazole)
Description: Sugar pill manufactured to mimic Esomeprazole
Study: NCT03417050

Intervention type: OTHER
Intervention: No intervention will take place for this retrospective and observational study.
Description: No intervention will take place for this retrospective and observational study.

Intervention type: OTHER
Intervention: No intervention will take place for this retrospective and observational study.
Description: No intervention will take place for this retrospective and observational study.
Study: NCT00889044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel by chewing
Description: 600 mg clopidogrel by chewing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo p.o
Study: NCT04433507

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy
Description: Laparoscopic sleeve gastrectomy (LSG) is performed through a standard 5-port technique. After dissection of the greater curvature of the stomach, a narrow tube-like stomach is created after stapling off the lateral aspect of the stomach using a 40 French bougie as a guide.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleeve gastrectomy
Description: Laparoscopic sleeve gastrectomy (LSG) is performed through a standard 5-port technique. After dissection of the greater curvature of the stomach, a narrow tube-like stomach is created after stapling off the lateral aspect of the stomach using a 40 French bougie as a guide.
Study: NCT02134405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole tablets 20mg o.d. for 8 weeks
Study: NCT00778505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: closed-loop administration using bispectral index as the controller

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil
Description: closed-loop administration using bispectral index as the controller
Study: NCT04936984

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: abaloparatide-sMTS (Patheon)
Description: single-dose administration of abaloparatide 300 μg applied to the thigh for 5 minutes

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: abaloparatide-sMTS (Kindeva)
Description: single-dose administration of abaloparatide 300 μg applied to the thigh for 5 minutes

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: abaloparatide-sMTS (Kindeva)
Description: single-dose administration of abaloparatide 300 μg applied to the thigh for 5 minutes

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: abaloparatide-sMTS (Kindeva)
Description: single-dose administration of abaloparatide 300 μg applied to the thigh for 5 minutes

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: abaloparatide-sMTS (Kindeva)
Description: single-dose administration of abaloparatide 300 μg applied to the thigh for 5 minutes

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: abaloparatide-sMTS (Patheon)
Description: single-dose administration of abaloparatide 300 μg applied to the thigh for 4 minutes

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: abaloparatide-sMTS (Patheon)
Description: single-dose administration of abaloparatide 300 μg applied to the thigh for 4 minutes

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: abaloparatide-sMTS (Patheon)
Description: single-dose administration of abaloparatide 300 μg applied to the thigh for 4 minutes

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: abaloparatide-sMTS (Patheon)
Description: single-dose administration of abaloparatide 300 μg applied to the thigh for 4 minutes

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: abaloparatide-sMTS (Patheon)
Description: single-dose administration of abaloparatide 300 μg applied to the thigh for 7 minutes
Study: NCT00778505

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: manual administration according bispectral index values

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: manual administration according bispectral index values
Study: NCT03212222

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peek Acuity
Description: Cell phone application for visual acuity screening
Study: NCT04936984

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: abaloparatide-sMTS (Patheon)
Description: single-dose administration of abaloparatide 300 μg applied to the thigh for 7 minutes

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: abaloparatide-sMTS (Patheon)
Description: single-dose administration of abaloparatide 300 μg applied to the thigh for 7 minutes
Study: NCT04433507

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hiatal Hernia repair
Description: Hiatal hernia repair consists in a circumferential dissection of the diaphragmatic crura to achieve an intra abdominal esophageal length of 2-3 cm. The crura will then be closed anteriorly and posteriorly using nonabsorbable sutures.
Study: NCT00896532

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Romosozumab
Description: Administered by subcutaneous injection QM or Q3M.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: Administered orally once a week
Study: NCT03212222

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Visual Screening
Description: Visual screening exam conducted in Duke University Eye Center
Study: NCT04022798

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise, manual therapy
Description: Participants were randomly assigned into treatment (n=15) or control group (n=15). Participants in each group received 12 treatment sessions of 45 minutes each, 2 days a week for 6 consecutive weeks.~For each group, a menu of a lumbar stabilization program was designed. This program included 8 levels of exercise ( single leg knee to chest stretch, double leg knee to chest, supine piriformis stretch, supine hamstring stretch, lower trunk rotation stretch, lumbar rotation stretch, pelvic tilt, pelivic tilt with alternative legs). Exercises were tailored for each individual ability and, if possible, progressed at each session which would last approximately 30 minutes. Each single exercise was repeated many times based on the patient's clinical condition. All sessions were provided by physiotherapists.
Study: NCT00896532

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: Teriparatide 20 μg administered by subcutaneous injection once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Romosozumab
Description: Administered by subcutaneous injection
Study: NCT04022798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise, manual therapy
Description: Participants were randomly assigned into treatment (n=15) or control group (n=15). Participants in each group received 12 treatment sessions of 45 minutes each, 2 days a week for 6 consecutive weeks.~For each group, a menu of a lumbar stabilization program was designed. This program included 8 levels of exercise ( single leg knee to chest stretch, double leg knee to chest, supine piriformis stretch, supine hamstring stretch, lower trunk rotation stretch, lumbar rotation stretch, pelvic tilt, pelivic tilt with alternative legs). Exercises were tailored for each individual ability and, if possible, progressed at each session which would last approximately 30 minutes. Each single exercise was repeated many times based on the patient's clinical condition. All sessions were provided by physiotherapists.
Study: NCT03148704

Intervention type: DRUG
Intervention: palonosetron hydrochloride capsules
Description: Collect all the patients' safty and efficacy data as long as they use palonosetron hydrochloride capsules(Ruo Shan®) .Specific methods of using the drugs are not limited .
Study: NCT01138436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEBO Wound Ointment (MEBO)
Description: Topical application once a day
Study: NCT00896532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Denosumab 60 mg administered by subcutaneous injection Q6M

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Denosumab
Description: Denosumab 60 mg administered by subcutaneous injection Q6M

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab 60 mg administered by subcutaneous injection Q6M

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab 60 mg administered by subcutaneous injection Q6M

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab 60 mg administered by subcutaneous injection Q6M
Study: NCT01138436

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Application of Profore multilayer compression bandage system
Study: NCT03567174

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated care van (ICV)
Description: Structural service delivery intervention
Study: NCT01903317

Intervention type: OTHER
Intervention: Topical Therapy
Description: Subjects will continue use of topical therapy (e.g. topical corticosteroids, keratolytic agents, anthralin, coal tar, vitamin D analogs, retinoids) for their psoriasis as if they were not participating in this study.

Intervention type: OTHER
Intervention: Phototherapy and Systemic Therapy
Description: Subjects will continue use of phototherapy (e.g. ultraviolet B \[UVB\] or ultraviolet A and psoralen \[PUVA\]) and systemic therapy (e.g. methotrexate, cyclosporine) for their psoriasis as if they were not participating in this study.

Intervention type: OTHER
Intervention: Biologic Therapy
Description: Subjects will continue use of biologic therapy (e.g. etanercept, adalimumab, ustekinumab) for their psoriasis as if they were not participating in this study.
Study: NCT03164889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Macrophage-colony Stimulating Factor
Description: The intervention drug was used as an immunomodulator in order to improve rates of HBsAg loss and HBeAg loss.
Study: NCT00896532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab 60 mg administered by subcutaneous injection Q6M

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab 60 mg administered by subcutaneous injection Q6M
Study: NCT03164889

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Antiviral drug for hepatitis b virus (HBV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Antiviral drug for hepatitis b virus (HBV)
Study: NCT01472393

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Description: The CR group will receive either 1g or 3g of Cr monohydrate (Creapure®) per day throughout the trial. The dose of creatine will be formulated in a tablet.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: dextrose (placebo)
Description: The placebo group will be given the same dose of dextrose formulated in a tablet to be consumed under the same conditions. The two types of tablets will not be distinguishable from each other having the same appearance, taste and smell.
Study: NCT01263860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa2a
Description: patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa2a
Description: patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks
Study: NCT02554370

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational programme
Description: 4 sessions of psychoeducation before and 3 after surgery for subthalamic deep brain stimulation
Study: NCT04061005

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold snare polypectomy
Description: CSP, which does not include electrocautery to do a polypectomy with a snare.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hot snare polypectomy
Description: HSP, which uses the electrocautery to do a polypectomy with a snare.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic margin observation method
Description: Endoscopic margin observation method, After rinsing the polyp specimen with physiological saline, fully natural extension, fixing it to the foam board with a needle, and observing the margin with a colonoscope or a magnifying colonoscope near-focus mode to determine whether there is residual polyp tissue.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic margin observation method
Description: Endoscopic margin observation method, After rinsing the polyp specimen with physiological saline, fully natural extension, fixing it to the foam board with a needle, and observing the margin with a colonoscope or a magnifying colonoscope near-focus mode to determine whether there is residual polyp tissue.
Study: NCT00727961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin hydrochloride
Description: Caelyx Intravenous, 50 mg/m\^2 (60 minute infusion) on day 1, every 4 weeks, during 6 cycles
Study: NCT01856426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP239

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00336622

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Splint fabricated by an OT versus an off-the-shelf splint
Description: Experimental:~Custom-made splint and tendon-nerve gliding exercises Custom-made splint and no tendon-nerve gliding exercises~Control:~Control: Off-the-shelf splint and tendon-nerve gliding exercises Off-the-shelf splint and no tendon-nerve gliding exercises

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Splint fabricated by an OT versus an off-the-shelf splint
Description: Experimental:~Custom-made splint and tendon-nerve gliding exercises Custom-made splint and no tendon-nerve gliding exercises~Control:~Control: Off-the-shelf splint and tendon-nerve gliding exercises Off-the-shelf splint and no tendon-nerve gliding exercises
Study: NCT02189941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone sustained-release
Description: Deferiprone sustained-release tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone sustained-release
Description: Deferiprone sustained-release tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferiprone immediate-release
Description: Deferiprone immediate-release tablets
Study: NCT04453462

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic carpal tunnel release under local direct median nerve block
Description: local direct median nerve block is performed by surgeon using the 1%xylocaine with adrenaline 12 mL(5 mL subcutaneous at incision site and 7 mL over median nerve) (maximum dose 7 mg/kg) before the endoscopic carpal tunnel release(1-portal Agee technique)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic carpal tunnel release under brachial plexus block
Description: brachial plexus block under ultrasound-guided is performed by experienced single anesthesiologist using the 1%xylocaine with adrenaline 15 mL (maximum dose 7 mg/kg) before the endoscopic carpal tunnel release(1-portal Agee technique)
Study: NCT04936984

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: abaloparatide-sMTS (Patheon)
Description: single-dose administration of abaloparatide 300 μg applied to the thigh for 7 minutes
Study: NCT02512484

Intervention type: PROCEDURE
Intervention: venepuncture, sputum collection, xray
Description: venepuncture, sputum collection, xray
Study: NCT03390842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC101
Description: Oral suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral suspension
Study: NCT02679963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02030899

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cage fusion
Description: Randomized selection of surgery type

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Plate fusion
Description: Randomized selection of surgery type
Study: NCT01566084

Intervention type: DRUG
Group type: OTHER
Intervention: Slow sodium tablets
Description: The normal salt condition is maintained with 2300 mg / day in the form of slowly released salt (NaCl) tablets.

Intervention type: OTHER
Group type: OTHER
Intervention: placebo
Description: Placebo tablets are administered to maintain the low sodium condition.
Study: NCT03835793

Intervention type: DIAGNOSTIC_TEST
Intervention: CAC-score
Description: Testing for possible unfavourable health effects of early surgical menopause
Study: NCT00896532

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Denosumab
Description: Administered by subcutaneous injection Q6M

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Denosumab
Description: Administered by subcutaneous injection Q6M
Study: NCT02656225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ejiao compound
Description: 20ml,twice daily, orally after breakfast Duration:4 weeks
Study: NCT00896532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Denosumab
Description: Administered by subcutaneous injection Q6M

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Denosumab
Description: Administered by subcutaneous injection Q6M

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Denosumab
Description: Administered by subcutaneous injection Q6M

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Denosumab
Description: Administered by subcutaneous injection Q6M

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Denosumab
Description: Administered by subcutaneous injection Q6M